肿瘤细胞治疗研究
英文原题：HPV-positive HNSCC and Fc-silent PD-1 blockade: a clinical discrepancy that raises next immunological questions.
近期针对Fc沉默型抗程序性细胞死亡蛋白-1（PD-1）抗体finotonlimab的3期试验显示，在复发/转移性头颈部鳞状细胞癌（HNSCC）中具有令人鼓舞的临床活性。
近期针对Fc沉默型抗程序性细胞死亡蛋白-1（PD-1）抗体finotonlimab的3期试验在复发/转移性头颈部鳞状细胞癌（HNSCC）中显示出有前景的临床活性。然而，出现了一个意外发现：HPV阳性患者——通常对PD-1阻断有应答——似乎并未获益，亚组HR倾向于对照组。这一临床差异提出了重要的机制性问题。我们假设，Fcγ受体（FcγR）介导功能的消除，虽然旨在保留PD-1 + T细胞，但可能无意中削弱了在病毒驱动肿瘤中尤其相关的先天免疫机制。在免疫炎症型HPV阳性HNSCC中，抗肿瘤活性可能不仅依赖于T细胞激活，还依赖于FcγR依赖的髓系细胞和NK 细胞功能。这些考虑促使进一步评估Fc工程化如何与肿瘤免疫微环境相互作用，尤其是在病毒相关癌症中。我们建议在未来研究中进行实验验证和分层分析，以阐明这些情境特异性效应。
The recent phase 3 trial of the Fc-silent anti-programmed cell death protein-1 (PD-1) antibody finotonlimab demonstrated promising clinical activity in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). However, an unexpected finding emerged: human papillomavirus (HPV)-positive patients-typically responsive to PD-1 blockade-did not appear to benefit, with a subgroup HR favoring the control arm. This clinical discrepancy raises important mechanistic questions. We hypothesize that the abrogation of Fcγ receptor (FcγR)-mediated functions, while designed to preserve PD-1 + T cells, may inadvertently attenuate innate immune mechanisms that are especially relevant in virally driven tumors. In immune-inflamed HPV-positive HNSCC, antitumor activity may depend not only on T-cell activation but also on FcγR-dependent myeloid and natural killer cell function. These considerations prompt further evaluation of how Fc engineering may interact with tumor immune contexture, particularly in virally associated cancers. We suggest experimental validation and stratified analysis in future studies to clarify these context-specific effects.
MEMBER ACCOUNT
登录成功会直接打开下一页。
